MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET 2019-2027

MARKET OUTLOOK
Triton’s report on the liquid biopsy market in the Middle East and Africa states that it is expected to grow with a CAGR of 27.21% in the forecast period 2019-2027.
The UAE, Turkey, South Africa, Saudi Arabia and countries in rest of MEA together form the market for liquid biopsy in the Middle East and African region.
The cancer early detection market is very attractive for sequencing. An important consideration for liquid biopsy tests is that they are highly specific; that is, they do not produce false positives. If tumor DNA is detected in the screening test, it means that the person has cancer. The overall driving force for the cancer early detection market is the fact that the earlier cancer is detected, the better the patient’s chances of overall survival and recovery. On the other hand, diagnostic & reference laboratories have adopted liquid biopsy tests to cater to the growing needs of oncology modalities and cancer treatment delivery. Physicians’ laboratories cater to a large patient pool and hence hold a majority share in the market. Preliminary liquid biopsy tests executed in physician laboratories can also indicate early stages of cancer, therapeutic effect on cancer and also cancer recurrence.
COMPETITIVE OUTLOOK
Agilent Technologies, Inc., Argon Medical Devices, Inc., Cintec Medical Ltd., Ad-Tech Medical Instrument Corp., QIAGEN N.V., Planmeca Oy, Cardinal Health, Inc. and Fischer Medical Technologies LLC are the distinguished names in the liquid biopsy market.

TABLE OF CONTENT
1. MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHT
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF RIVALRY
2.4. REGULATORY FRAMEWORK
2.5. KEY MARKET TRENDS
2.6. KEY LIQUID BIOPSY INITIATIVES
2.7. MARKET ATTRACTIVENESS INDEX
2.8. MARKET DRIVERS
2.8.1. CANCER CASES IN OLDER POPULACE ARE SIGNIFICANTLY INCREASING
2.8.2. DIAGNOSTIC CENTERS ARE IN DEMAND
2.8.3. TISSUE/TUMOR-AGNOSTIC DRUGS USAGE ARE INCREASING
2.8.4. RISE IN USAGE OF PRECISION MEDICINE
2.9. MARKET RESTRAINTS
2.9.1. HIGH COST OF TEST
2.9.2. LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPs)
2.10. MARKET OPPORTUNITIES
2.10.1. ADVANCEMENT IN TECHNOLOGY
2.10.2. RISING NUMBER OF CANCER PATIENTS
2.11. MARKET CHALLENGES
2.11.1. LACK OF REIMBURSEMENT
2.11.2. SKILLED PROFESSIONALS ARE QUITE LESS IN NUMBER
3. LIQUID BIOPSY MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. PROSTATE CANCER
3.2. MELANOMA CANCER
3.3. BREAST CANCER
3.4. COLORECTAL CANCER
3.5. LUNG CANCER
3.6. OTHER TYPES OF CANCER
3.7. NON-ONCOLOGY APPLICATIONS
4. LIQUID BIOPSY MARKET OUTLOOK - BY PRODUCT
4.1. CELL-FREE DNA (CFDNA)
4.2. CIRCULATING TUMOR CELLS (CTCS)
4.3. CIRCULATING TUMOR DNA (CTDNA)
4.4. EXTRACELLULAR VESICLES AND OTHERS
5. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PURPOSE
5.1. MONITORING
5.2. THERAPY GUIDANCE
5.3. EARLY DETECTION/SCREENING
5.4. DIAGNOSIS
6. LIQUID BIOPSY MARKET OUTLOOK - BY END-USER
6.1. HOSPITALS
6.2. PHYSICIANS’ OFFICE LABORATORIES
6.3. CLINICAL DIAGNOSTIC LABORATORIES
7. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PLATFORM
7.1. MICROARRAY
7.2. NGS
7.3. PROTEOMICS
7.4. PCR
7.5. OTHER ANALYSIS PLATFORMS
8. LIQUID BIOPSY MARKET OUTLOOK - BY BIOMARKER TYPE
8.1. NUCLEIC ACIDS
8.2. PROTEINS
8.3. EXTRACELLULAR VESICLES
8.4. CELLS
9. LIQUID BIOPSY MARKET OUTLOOK - BY CLINICAL APPLICATION
9.1. TREATMENT MONITORING
9.2. PROGNOSIS & REOCCURRENCE MONITORING
9.3. TREATMENT SELECTION
9.4. DIAGNOSIS & SCREENING
10. LIQUID BIOPSY MARKET - REGIONAL OUTLOOK
10.1. MIDDLE EAST AND AFRICA
10.1.1. MARKET BY THERAPEUTIC APPLICATION
10.1.2. MARKET BY CLINICAL APPLICATION
10.1.3. MARKET BY BIOMARKER TYPE
10.1.4. MARKET BY ANALYSIS PLATFORM
10.1.5. MARKET BY ANALYSIS PURPOSE
10.1.6. MARKET BY PRODUCT
10.1.7. MARKET BY END-USER
10.1.8. COUNTRY ANALYSIS
10.1.8.1. SAUDI ARABIA
10.1.8.2. TURKEY
10.1.8.3. UNITED ARAB EMIRATES
10.1.8.4. SOUTH AFRICA
10.1.8.5. REST OF MIDDLE EAST & AFRICA
11. COMPETITIVE LANDSCAPE
11.1. AGILENT TECHNOLOGIES, INC.
11.2. BOSTON SCIENTIFIC CORPORATION
11.3. ARGON MEDICAL DEVICES, INC.
11.4. B. BRAUN MELSUNGEN AG
11.5. CINTEC MEDICAL LTD.
11.6. ROCHE DIAGNOSTICS CORPORATION
11.7. AD-TECH MEDICAL INSTRUMENT CORP.
11.8. I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
11.9. QIAGEN N.V.
11.10. BECTON, DICKINSON
11.11. PLANMECA OY
11.12. BIO-RAD LABORATORIES, INC.
11.13. CARDINAL HEALTH, INC.
11.14. COOK MEDICAL, INC.
11.15. FISCHER MEDICAL TECHNOLOGIES LLC
11.16. C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON AND COMPANY)
12. RESEARCH METHODOLOGY & SCOPE
12.1. RESEARCH SCOPE & DELIVERABLES
12.1.1. OBJECTIVES OF STUDY
12.1.2. SCOPE OF STUDY
12.2. SOURCES OF DATA
12.2.1. PRIMARY DATA SOURCES
12.2.2. SECONDARY DATA SOURCES
12.3. RESEARCH METHODOLOGY
12.3.1. EVALUATION OF PROPOSED MARKET
12.3.2. IDENTIFICATION OF DATA SOURCES
12.3.3. ASSESSMENT OF MARKET DETERMINANTS
12.3.4. DATA COLLECTION
12.3.5. DATA VALIDATION & ANALYSIS

LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
TABLE 2 LIQUID BIOPSY BIOMARKER CLASSES
TABLE 3 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 4 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 5 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 7 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 8 ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 9 DROPLET DIGITAL PCR INDUSTRIES
TABLE 10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 11 CELL DIFFERENTIATORS
TABLE 12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 13 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 2 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY PROSTATE CANCER 2019-2027 ($ MILLION)
FIGURE 3 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY MELANOMA CANCER 2019-2027 ($ MILLION)
FIGURE 4 TYPES OF BREAST CANCER
FIGURE 5 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY BREAST CANCER 2019-2027 ($ MILLION)
FIGURE 6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY COLORECTAL CANCER 2019-2027 ($ MILLION)
FIGURE 7 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY LUNG CANCER 2019-2027 ($ MILLION)
FIGURE 8 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY OTHER TYPES OF CANCER 2019-2027 ($ MILLION)
FIGURE 9 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY NON-ONCOLOGY APPLICATION 2019-2027 ($ MILLION)
FIGURE 10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY CELL-FREE DNA (CFDNA) 2019-2027 ($ MILLION)
FIGURE 11 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY CIRCULATING TUMOR CELLS (CTCS) 2019-2027 ($ MILLION)
FIGURE 12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY CIRCULATING TUMOR DNA (CTDNA) 2019-2027 ($ MILLION)
FIGURE 13 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES AND OTHERS 2019-2027 ($ MILLION)
FIGURE 14 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY MONITORING 2019-2027 ($ MILLION)
FIGURE 15 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY THERAPY GUIDANCE 2019-2027 ($ MILLION)
FIGURE 16 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY EARLY DETECTION/SCREENING 2019-2027 ($ MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY DIAGNOSIS 2019-2027 ($ MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY HOSPITALS 2019-2027 ($ MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY PHYSICIANS’ OFFICE LABORATORIES 2019-2027 ($ MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY CLINICAL DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY NGS 2019-2027 ($ MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY PROTEOMICS 2019-2027 ($ MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY PCR 2019-2027 ($ MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY OTHER ANALYSIS PLATFORM 2019-2027 ($ MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY NUCLEIC ACIDS 2019-2027 ($ MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY PROTEINS 2019-2027 ($ MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES 2019-2027 ($ MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY CELLS 2019-2027 ($ MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY TREATMENT MONITORING 2019-2027 ($ MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY PROGNOSIS & REOCCURRENCE MONITORING 2019-2027 ($ MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY TREATMENT SELECTION 2019-2027 ($ MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY DIAGNOSIS & SCREENING 2019-2027 ($ MILLION)
FIGURE 34 SAUDI ARABIA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 35 TURKEY LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 36 UNITED ARAB EMIRATES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 37 SOUTH AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 38 REST OF MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)